Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 7/20 | 0.53 |
| ▸ | PDCD1 | Q15116 | 3/20 | 0.53 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.50 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.48 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10272681 | 1.00 | CD274 (0.53) | CD274PDCD1NPBWR1MCHR1SMN1; SMN2 | |
| SCHEMBL2036101 | 1.00 | CD274 (0.53) | CD274PDCD1NPBWR1MCHR1SMN1; SMN2 | |
| SCHEMBL3148407 | 0.86 | CYP1A2 (0.51) | CD274PDCD1NPBWR1MCHR1SMN1; SMN2 | |
| SCHEMBL1817183 | 0.86 | CYP1A2 (0.51) | CD274PDCD1NPBWR1MCHR1SMN1; SMN2 | |
| SCHEMBL2032294 | 0.86 | CYP1A2 (0.51) | CD274PDCD1NPBWR1MCHR1SMN1; SMN2 | |
| SCHEMBL1819248 | 0.86 | CYP1A2 (0.60) | CD274PDCD1MCHR1SMN1; SMN2CYP1A2 | |
| SCHEMBL1972076 | 0.86 | CYP1A2 (0.60) | CD274PDCD1MCHR1SMN1; SMN2CYP1A2 | |
| SCHEMBL2587055 | 0.86 | CYP1A2 (0.60) | CD274PDCD1MCHR1SMN1; SMN2CYP1A2 | |
| SCHEMBL15652882 | 0.85 | ALDH1A1 (0.54) | CD274PDCD1SMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL1819133 | 0.85 | IDO1 (0.53) | CD274PDCD1SMN1; SMN2CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3154568-A1 | NON-CANONICAL INSULINS AND THEIR USES | California Institute of Technology (US) | 2017-04-19 | — | — | EP | claimed |
| WO-2015191705-A1 | NON-CANONICAL INSULINS AND THEIR USES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2015-12-17 | — | — | WO | claimed |
| US-20150353619-A1 | Non-Canonical Insulins and Their Uses | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2015-12-10 | — | — | US | claimed |
| EP-4694932-A2 | COMPOUNDS CONTAINING ONE OR MORE DIBORONATES AND RELATED INSULIN ANALOGS | Protomer Technologies Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250249074-A1 | GLUCOSE RESPONSIVE INSULINS | PROTOMER TECHNOLOGIES INC. | 2025-08-07 | — | — | US | disclosed |
| US-20250108031-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES, LLC | 2025-04-03 | — | — | US | disclosed |
| US-12214018-B2 | Glucose responsive insulins | PROTOMER TECHNOLOGIES, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20240425528-A1 | AROMATIC BORON-CONTAINING COMPOUNDS AND RELATED INSULIN ANALOGS | PROTOMER TECH INC (US) | 2024-12-26 | — | — | US | disclosed |
| US-20240400637-A1 | COMPOUNDS CONTAINING ONE OR MORE DIBORONATES AND RELATED INSULIN ANALOGS | PROTOMER TECHNOLOGIES INC. | 2024-12-05 | — | — | US | disclosed |
| US-20240374735-A1 | AROMATIC BORON-CONTAINING COMPOUNDS AND INSULIN ANALOGS | PROTOMER TECHNOLOGIES INC. | 2024-11-14 | — | — | US | disclosed |
| US-12139502-B2 | Aromatic boron-containing compounds and related insulin analogs | PROTOMER TECHNOLOGIES INC. (US) | 2024-11-12 | — | — | US | disclosed |
| EP-1948243-A2 | POLYCATION-POLYANION COMPLEXES, COMPOSITIONS AND METHODS OF USE THEREOF | Aeris Therapeutics, Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20080057491-A1 | Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-03-06 | — | — | US | disclosed |
| WO-2008022015-A2 | RETRO-INVERSO INCRETIN ANALOGUES, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2007146104-A2 | SUBSTRATES AND INHIBITORS OF ANTIPLASMIN CLEAVING ENZYME AND METHODS OF USE | MCKEE PATRICK A (US) | 2007-12-21 | — | — | WO | disclosed |
| EP-1863513-A2 | POTENT AND SPECIFIC IMMUNOPROTEASOME INHIBITORS | The University of North Carolina at Chapel Hill (US) | 2007-12-12 | — | — | EP | disclosed |
| WO-2007055950-A2 | POLYCATION-POLYANION COMPLEXES, COMPOSITIONS AND METHODS OF USE THEREOF | AERIS THERAPEUTICS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070110813-A1 | Polycation-polyanion complexes, compositions and methods of use thereof | AERIS THERAPEUTICS, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| US-20060241056-A1 | Potent and specific immunoproteasome inhibitors | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2006-10-26 | — | — | US | disclosed |
| WO-2006099261-A2 | POTENT AND SPECIFIC IMMUNOPROTEASOME INHIBITORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241056-A1 | Potent and specific immunoproteasome inhibitors | SERPINB1, DNPEP, PSMB2 | CD274 1311/4885PDCD1 541/4885NPBWR1 3419/4885 |
| US-20250108031-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | FAP, FIBP, GOT1 | CD274 2533/4885PDCD1 1540/4885NPBWR1 3549/4885 |
| US-20250249074-A1 | GLUCOSE RESPONSIVE INSULINS | GLP1R, GPR119, IAPP | CD274 324/4885PDCD1 1581/4885NPBWR1 112/4885 |
| US-20240425528-A1 | AROMATIC BORON-CONTAINING COMPOUNDS AND RELATED INSULIN ANALOGS | IAPP, GPR119, INSR | CD274 4421/4885PDCD1 3303/4885NPBWR1 160/4885 |
| US-12214018-B2 | Glucose responsive insulins | GLP1R, GPR119, IAPP | CD274 338/4885PDCD1 1584/4885NPBWR1 113/4885 |
| US-20150353619-A1 | Non-Canonical Insulins and Their Uses | IAPP, IDE, INSR | CD274 4744/4885PDCD1 3844/4885NPBWR1 148/4885 |
| US-20240400637-A1 | COMPOUNDS CONTAINING ONE OR MORE DIBORONATES AND RELATED INSULIN ANALOGS | GPR119, INSR, IAPP | CD274 4022/4885PDCD1 2227/4885NPBWR1 203/4885 |
| US-12139502-B2 | Aromatic boron-containing compounds and related insulin analogs | IAPP, GPR119, INSR | CD274 4421/4885PDCD1 3303/4885NPBWR1 160/4885 |
| US-20240374735-A1 | AROMATIC BORON-CONTAINING COMPOUNDS AND INSULIN ANALOGS | IAPP, GPR119, BRCA1 | CD274 4123/4885PDCD1 2239/4885NPBWR1 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.